4.4 Article

Migraine prevalence by age and sex in the United States: A life-span study

期刊

CEPHALALGIA
卷 30, 期 9, 页码 1065-1072

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102409355601

关键词

migraine; menstrual migraine; headache; epidemiology; menstruation; paediatric headache

资金

  1. Endo Pharmaceuticals Inc., Chadds Ford, Pennsylvania, USA
  2. Advanced Bionics
  3. Allergan Pharmaceuticals
  4. AstraZeneca
  5. Boehringer-Ingelheim
  6. Bristol-Myers Squibb
  7. Cierra
  8. Endo Pharmaceuticals Inc.
  9. GlaxoSmithKline
  10. Minster
  11. Merck Co., Inc.
  12. Neuralieve
  13. Novartis
  14. OrthoMcNeil Neurologics Inc.
  15. Pfizer Inc
  16. Pozen Inc.
  17. ProEthics, Ltd
  18. St Jude Children's Research Hospital

向作者/读者索取更多资源

The present study assessed age-and sex-specific patterns of migraine prevalence in a US population of 40,892 men, women, and children who participated in the 2003 National Health Interview Survey. Gaussian mixture models characterised the relationship between migraine, age, and sex. Migraine prevalence was 8.6% (males), 17.5% (females), and 13.2% (overall) and showed a bimodal distribution in both sexes (peaking in the late teens and 20s and around 50 years of age). Rate of change in migraine prevalence for both sexes increased the fastest from age 3 years to the mid-20s. Beyond the age of 10 years, females had a higher prevalence of migraine than males. The prevalence ratio for females versus males was highest during the female reproductive/child-bearing years, consistent with a relationship between menstruation and migraine. After age 42 years, the prevalence ratio was approximately 2-fold higher in women.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据